{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Kyverna Therapeutics (\"Kyverna\") located in Berkeley, CA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/02/18/2021-03221.html","cfr_references":[],"citation":"86 FR 10092","comment_url":null,"comments_close_on":"2021-03-05","correction_of":null,"corrections":[],"dates":"Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 5, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-03221","effective_on":null,"end_page":10093,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/02/18/2021-03221.xml","html_url":"https://www.federalregister.gov/documents/2021/02/18/2021-03221/prospective-grant-of-an-exclusive-patent-license-allogeneic-therapy-for-the-treatment-of-autoimmune","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-03221?publication_date=2021-02-18","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-02-18/2021-03221/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":474,"last_updated":"2026-06-23 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-02-18/pdf/2021-03221.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-03221.pdf?1613569526","publication_date":"2021-02-18","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/02/18/2021-03221.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:34:48Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":10092,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Allogeneic Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19","toc_doc":"Allogeneic Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}